MILIND JAVLE to Antibodies, Monoclonal
This is a "connection" page, showing publications MILIND JAVLE has written about Antibodies, Monoclonal.
Connection Strength
0.701
-
Randomized, phase I/II study of gemcitabine plus IGF-1R antagonist (MK-0646) versus gemcitabine plus erlotinib with and without MK-0646 for advanced pancreatic adenocarcinoma. J Hematol Oncol. 2018 05 30; 11(1):71.
Score: 0.260
-
Ramucirumab: successfully targeting angiogenesis in gastric cancer. Clin Cancer Res. 2014 Dec 01; 20(23):5875-81.
Score: 0.202
-
Hypertension secondary to anti-angiogenic therapy: experience with bevacizumab. Anticancer Res. 2007 Sep-Oct; 27(5B):3465-70.
Score: 0.123
-
Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study. Br J Cancer. 2009 Jun 16; 100(12):1842-5.
Score: 0.035
-
Epidermal growth factor receptor-directed therapy in esophageal cancer. Oncology. 2007; 73(5-6):281-9.
Score: 0.032
-
Phase 2 trial of bintrafusp alfa as second-line therapy for patients with locally advanced/metastatic biliary tract cancers. Hepatology. 2023 09 01; 78(3):758-770.
Score: 0.023
-
4-1BB Agonist Focuses CD8+ Tumor-Infiltrating T-Cell Growth into a Distinct Repertoire Capable of Tumor Recognition in Pancreatic Cancer. Clin Cancer Res. 2017 Dec 01; 23(23):7263-7275.
Score: 0.016
-
Phase II trial of cetuximab, gemcitabine, and oxaliplatin followed by chemoradiation with cetuximab for locally advanced (T4) pancreatic adenocarcinoma: correlation of Smad4(Dpc4) immunostaining with pattern of disease progression. J Clin Oncol. 2011 Aug 01; 29(22):3037-43.
Score: 0.010